Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.

@article{Sykes2016FevipiprantA,
  title={Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.},
  author={David A. Sykes and Michelle E Bradley and Darren M Riddy and Elizabeth Willard and John R Reilly and Asadh Miah and Carsten Bauer and Simon J. Watson and David A Sandham and Gerald Dubois and Steven J Charlton},
  journal={Molecular pharmacology},
  year={2016},
  volume={89 5},
  pages={593-605}
}
Here we describe the pharmacologic properties of a series of clinically relevant chemoattractant receptor-homologous molecules expressed on T-helper type 2 (CRTh2) receptor antagonists, including fevipiprant (NVP-QAW039 or QAW039), which is currently in development for the treatment of allergic diseases. [(3)H]-QAW039 displayed high affinity for the human… CONTINUE READING
  • Blog articles referencing this paper

    • FEVIPIPRANT

      New Drug Approvals · Dec 12, 2017

    • Don't see an article that should be here?

  • Presentations referencing similar topics